• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    6/18/24 8:07:53 AM ET
    $AMIX
    $AZTR
    $BIOL
    $DMTK
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMIX alert in real time by email

    Gainers

    • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 63.8% to $0.28 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. As per the news, the Q4 earnings report came out yesterday.
    • Qualigen Therapeutics (NASDAQ:QLGN) stock rose 31.57% to $0.23. The company's market cap stands at $1.4 million.
    • Mustang Bio (NASDAQ:MBIO) shares rose 30.66% to $0.98. The company's market cap stands at $27.6 million.
    • Autonomix Medical (NASDAQ:AMIX) stock rose 25.92% to $1.7. The market value of their outstanding shares is at $32.0 million.
    • Silk Road Medical (NASDAQ:SILK) shares moved upwards by 23.9% to $26.85. The market value of their outstanding shares is at $1.0 billion.
    • Onconetix (NASDAQ:ONCO) shares moved upwards by 22.73% to $0.2. The market value of their outstanding shares is at $4.3 million.

    Losers

    • DermTech (NASDAQ:DMTK) shares fell 50.4% to $0.17 during Tuesday's pre-market session. The company's market cap stands at $5.7 million.
    • Biolase (NASDAQ:BIOL) stock fell 42.0% to $0.09. The company's market cap stands at $2.8 million.
    • Zentalis Pharma (NASDAQ:ZNTL) shares decreased by 28.61% to $5.99. The market value of their outstanding shares is at $425.3 million.
    • Virpax Pharmaceuticals (NASDAQ:VRPX) stock declined by 15.04% to $0.65. The market value of their outstanding shares is at $1.7 million.
    • Anitra (AMEX:AZTR) shares decreased by 12.84% to $0.2. The company's market cap stands at $5.8 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) stock declined by 10.72% to $5.0. The company's market cap stands at $2.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMIX
    $AZTR
    $BIOL
    $DMTK

    CompanyDatePrice TargetRatingAnalyst
    Zentalis Pharmaceuticals Inc.
    $ZNTL
    8/12/2024$4.00Underperform → Neutral
    Wedbush
    Silk Road Medical Inc.
    $SILK
    7/11/2024Buy → Sell
    Argus
    Zentalis Pharmaceuticals Inc.
    $ZNTL
    6/20/2024$28.00 → $5.00Buy → Neutral
    UBS
    Zentalis Pharmaceuticals Inc.
    $ZNTL
    6/18/2024$42.00 → $6.00Buy → Hold
    Jefferies
    Zentalis Pharmaceuticals Inc.
    $ZNTL
    6/18/2024$38.00 → $8.00Overweight → Equal-Weight
    Morgan Stanley
    Zentalis Pharmaceuticals Inc.
    $ZNTL
    6/18/2024$15.00 → $4.00Neutral → Underperform
    Wedbush
    Zentalis Pharmaceuticals Inc.
    $ZNTL
    6/18/2024Overweight → Equal Weight
    Wells Fargo
    Silk Road Medical Inc.
    $SILK
    3/7/2024$24.00Hold → Buy
    Argus
    More analyst ratings

    $AMIX
    $AZTR
    $BIOL
    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Bruns Ingmar sold $7,998 worth of shares (3,297 units at $2.43), decreasing direct ownership by 9% to 33,332 units (SEC Form 4)

    4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

    2/10/26 9:10:49 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PAO and PFO Vultaggio Vincent sold $97,557 worth of shares (40,224 units at $2.43), decreasing direct ownership by 22% to 146,506 units (SEC Form 4)

    4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

    2/10/26 9:10:25 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Eastland Julia Marie sold $21,239 worth of shares (8,755 units at $2.43), decreasing direct ownership by 10% to 79,133 units (SEC Form 4)

    4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

    2/10/26 9:09:41 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $AZTR
    $BIOL
    $DMTK
    SEC Filings

    View All

    SEC Form DEFA14A filed by Azitra Inc

    DEFA14A - Azitra, Inc. (0001701478) (Filer)

    3/5/26 4:36:04 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    3/5/26 4:35:26 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    2/27/26 5:02:57 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $AZTR
    $BIOL
    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zentalis Pharma upgraded by Wedbush with a new price target

    Wedbush upgraded Zentalis Pharma from Underperform to Neutral and set a new price target of $4.00

    8/12/24 8:08:44 AM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silk Road Medical downgraded by Argus

    Argus downgraded Silk Road Medical from Buy to Sell

    7/11/24 7:47:06 AM ET
    $SILK
    Medical/Dental Instruments
    Health Care

    Zentalis Pharma downgraded by UBS with a new price target

    UBS downgraded Zentalis Pharma from Buy to Neutral and set a new price target of $5.00 from $28.00 previously

    6/20/24 7:40:40 AM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $AZTR
    $BIOL
    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

    BRANFORD, Conn., March 5, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has cancelled the Company's special meeting of stockholders that was originally scheduled for February 6, 2026, but was adjourned due to a lack of quorum until March 6, 2026. About AzitraAzitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12,

    3/5/26 4:30:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Autonomix Medical Selected for Best Innovation Competition at CRT 2026

    THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its presentation titled, "Illuminating The Nervous System With Transvascular Precision-guided Technology," has been selected for oral presentation in the Best Innovation Competition at Cardiovascular Research Technologies (CRT) 2026. The presentation will be delivered by Chief Executive Officer, Brad Hauser, on Monday, March 9, 2026, from 4:19 PM to 4:27 PM ET in the International Ballroom – West. The CRT Best Innovation Competition highlights transformative tec

    3/5/26 8:45:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis

    THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC. The abstract titled, "Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes," will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 - 2:24p ET for Hypertension Therapies

    3/4/26 8:40:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    $AZTR
    $BIOL
    $DMTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Walters Group bought $7,751,968 worth of shares (6,459,973 units at $1.20) (SEC Form 4)

    4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

    1/8/26 4:57:05 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jin David bought $238 worth of shares (247 units at $0.96), increasing direct ownership by 633% to 286 units (SEC Form 4)

    4 - MUSTANG BIO, INC. (0001680048) (Issuer)

    12/30/25 4:15:14 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Myers Scott Dunseth bought $29,373 worth of shares (21,000 units at $1.40), increasing direct ownership by 8% to 281,192 units (SEC Form 4)

    4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

    4/30/25 5:07:20 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $AZTR
    $BIOL
    $DMTK
    Leadership Updates

    Live Leadership Updates

    View All

    Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

    Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's AgencyAn application will be filed with the FDA for Orphan Drug and Breakthrough Designation in Pemphigus, as well as in SJS/TENScinai sees potential for accelerated approval given the severity of these diseases, PC111's innovative, non-immunosuppressive mode of action and the lack of effective alternative treatmentsJERUSALEM, March 27, 2025 /PRNewswire/ -- Scinai Imm

    3/27/25 9:25:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

    Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and othe

    3/26/25 4:05:00 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

    Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate event to be held on January 29, 2025 at 8:00am ET to provide key updates on azenosertib clinical data, development and regulatory path SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a restructuring of its business operations and research and development organ

    1/28/25 4:05:00 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $AZTR
    $BIOL
    $DMTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    12/3/24 6:17:58 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    11/27/24 10:15:18 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

    SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

    11/14/24 4:28:57 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $AZTR
    $BIOL
    $DMTK
    Financials

    Live finance-specific insights

    View All

    Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

    JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the six months ended June 30, 2025. Six-Month 2025 Financial Summary  Revenues for the six months ended June 30, 2025, totaled $773 thousand, compared to $284 thousand for the six months ended June 30, 2024. The increase reflects the continued growth of the Company's CDMO business, which gener

    9/2/25 7:30:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

    JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025. Three (3) Months of 2025 Financial Summary Revenues for the three months ended March 31, 2025, totaled $586 thousand. The Company's CDMO unit began generating revenues in the second quarter ended June 30, 2024. As disclosed in the Company's Annual

    5/30/25 7:00:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

    BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

    2/24/25 8:30:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care